| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21:42 | Medicenna Therapeutics GAAP EPS of -$0.04 beats by $0.02 | 3 | Seeking Alpha | ||
| 15:59 | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 13:48 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update | 2 | GlobeNewswire (USA) | ||
| 04.11. | Medicenna Therapeutics Corp: Medicenna fills enrolment in MDNA11 trial | 7 | Stockwatch | ||
| 04.11. | Stocks in Play: Medicenna Therapeutics Corp. | 5 | Baystreet.ca | ||
| 26.10. | Medicenna Therapeutics Corp.: Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease | 1 | GlobeNewswire (USA) | ||
| 05.10. | Medicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026 | 2 | GlobeNewswire (USA) | ||
| 02.10. | Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual General and Special Meeting of Shareholders | 213 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines... ► Artikel lesen | |
| 24.09. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 24.09. | Medicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 14.08. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 14.08. | Medicenna Therapeutics Corp. GAAP EPS of -$0.06 | 1 | Seeking Alpha | ||
| 02.07. | Medicenna stock price target maintained at $2.50 by H.C. Wainwright | 2 | Investing.com | ||
| 26.06. | Medicenna Therapeutics Corp. GAAP EPS of -C$0.22 | 1 | Seeking Alpha | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights | 396 | GlobeNewswire (Europe) | MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer... ► Artikel lesen | |
| 11.06. | Medicenna Therapeutics Corp: Medicenna receives two U.S. patents | 1 | Stockwatch | ||
| 03.06. | Medicenna Therapeutics Corp: Medicenna highlights MDNA11 melanoma trial data | 3 | Stockwatch | ||
| 03.06. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 29.05. | Medicenna Therapeutics Corp: Medicenna Therapeutics closes $4.44M public offering | 1 | Stockwatch | ||
| 28.05. | Medicenna Therapeutics Corp.: Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs | 1 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | -0,24 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| COGENT BIOSCIENCES | 27,850 | +1,49 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| CG ONCOLOGY | 78,93 | -6,90 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| SUMMIT THERAPEUTICS | 10,660 | -9,81 % | Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback | ||
| PRAXIS PRECISION MEDICINES | 305,32 | -1,60 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| ERASCA | 13,900 | -7,95 % | Warum die Erasca-Aktie heute nachgibt: Düstere Verlustprognosen belasten den Kurs | ||
| TREVI THERAPEUTICS | 13,510 | +1,66 % | Trevi Therapeutics: Wie ein Nischenmedikament zum strategischen Hebel für den Milliardenmarkt Reizhusten werden könnte | Trevi Therapeutics steht kurz davor, mit Haduvio ein erstes Nischenprodukt in den US-Markt zu bringen und damit einen "specialty beachhead" zu etablieren, der als Plattform für eine mögliche Expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,640 | -1,43 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| EDGEWISE THERAPEUTICS | 42,020 | -3,80 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,720 | -6,37 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| JADE BIOSCIENCES | 15,400 | +0,42 % | Jade Biosciences forciert Autoimmun-Pipeline: Ambitionierte Pläne im 20-Milliarden-Dollar-Markt | ||
| KYMERA THERAPEUTICS | 121,49 | -3,43 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 51,11 | +2,80 % | Travere Therapeutics auf der Jefferies Global Healthcare Conference: Starkes FILSPARI-Wachstum, Pipeline-Fortschritte und verlängerter Patentschutz bis 2037 | ||
| TANGO THERAPEUTICS | 22,120 | -8,48 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| RAPPORT THERAPEUTICS | 23,760 | -4,27 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference |